Delivering Pharma’s Mega-Projects in a Resource-Constrained World: Part Two

As pharmaceutical manufacturers push forward with massive capital expansion plans, challenges go beyond simply breaking ground on new facilities—it’s also managing the growing complexity, uncertainty, and resource strain that come with executing mega-projects. Persistent supply chain disruption, extended equipment lead times, rising material costs, and workforce constraints are forcing companies to rethink how they plan, govern, and prioritize capital investments in an increasingly volatile environment.  In this episode of Off Script, we continued our conversation with Steve Cabano, president of Pathfinder, and Mark Christopher, vice president and head of the company’s pharmaceutical division, about the operational realities shaping large-scale pharmaceutical construction projects today. Pathfinder is a project management consulting firm. The discussion explores how post-pandemic supply chain instability and tariff uncertainty are impacting procurement strategies, scheduling assumptions, and project economics, with lead times for critical equipment stretching far beyond historical norms. We also examine the growing importance of portfolio-level governance as companies attempt to manage dozens of overlapping billion-dollar initiatives while maintaining existing operations, avoiding internal resource conflicts, and preparing for a future shaped by modularization, robotics, and AI-enabled project delivery.